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CASE  REPORT
Introduction
Primitive neuroectodermal tumor (PNET) and
tetralogy of Fallot (TOF) have never been reported to
coexist in 1 patient, although the tendency of
developing malignancy in patients with congenital
defects has been well documented.1 Extracranial PNET
is a small, round-cell malignancy of presumed neural
crest origin arising outside the central and sympathetic
nervous system, called peripheral PNET (pPNET). It
predominantly affects children and adolescents,
presenting a highly malignant clinical behavior. Recent
developments in cytogenetic analysis have revealed a
high frequency (up to 95%) of reciprocal translocation
t(11;22)(q24;q12) detected in pPNET,2,3 and a strong
association between TOF and chromosome 22q11
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microdeletion (del 22q11).4 As both of the genetic
defects involve chromosome 22q in the close region,
it is interesting for the pediatrician to investigate if
both pPNET and TOF could occur concurrently in
the same patient.
Case Report
In October 2004, an 11-month-old girl was admitted
to the pediatric ward of Taipei Veterans General
Hospital with the chief complaint of progressive lower
limb weakness in the past week. The patient was found
by her mother to have difficulty in standing and
crawling for 2 days. The infant had TOF, which had
been diagnosed after birth. In May 2004, because of
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moderate pulmonary stenosis (PS) and frequent
cyanotic spells, she had received cardiac catheterization
and balloon valvular dilatation for PS, and beta-blocker
(propranolol) had also been prescribed, after which
she was in a relatively stable condition and followed-
up regularly in the pediatric cardiology ward.
On this admission, physical examination revealed
decreased deep tendon reflex and muscle power in the
lower extremities. T-spine myelopathy was suggested.
Chest X-ray showed a mass shadow over the cardiac
region (Figure 1). Whole-spine magnetic resonance
imaging (MRI) revealed a large contrast-enhanced
tumor mass over the left paraspinal region (T4–T12),
with intraspinal extension causing severe compression
(Figure 2). Tumor markers, including _-fetoprotein,
`-homologous chorionic gonadotropin, urine
vanillylmandelic acid and urine catecholamine,
were within normal limits. Lactate dehydrogenase
315 U/L and neuron-specific enolase 14.52 ng/mL
were found.
For spinal decompression, emergency laminectomy
(from T5 to T9) and tumor biopsy were performed
on the third day of admission (October 6, 2004).
Hypervascular and reddish tumor masses in the epidural
space over T5–T9 were found. Pathology reported a
small  round-cel l  tumor with mild nuclear
pleomorphism, scant eosinophilic cytoplasm and a
fibrillary stroma (Figure 3). These cells were weakly
reactive for epithelial membrane antigen, and
nonreactive for glial fibrillary acidic protein. The MIB-
1 (a monoclonal antibody that detects cell-cycle–
associated Ki-67 antigen) labeling index was 30%.
Figure 1. Chest X-ray shows significantly widened upper
mediastinum with a mass shadow over the cardiac region.
Figure 2. (A) Whole-spine magnetic resonance imaging shows the
presence of a large paraspinal soft tissue mass (T4–T12; 10 = 7
= 3.5 cm in size). (B) The soft tissue mass with intraspinal
extension causes severe compression of the spinal cord around
the T7–T8 level.
The tumor was consistent with PNET. Peripheral
blood was taken for routine chromosome banding
studies and specialized interphase fluorescent in situ
hybridization studies for mapping to 22q11. However,
no chromosome abnormality was found.
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Nine days after surgery, chemotherapy was initiated
with alternative courses of VDC (vincristine, 1.5 mg/
m2 on day 1; doxorubicin, 37.5 mg/m2/day on days
1–2; cyclophosphamide, 1.2 g/m2 on day 1) and IE
(ifosfamide, 1.8 g/m2/day on days 1–5; etoposide,
100 mg/m2/day on days 1–5) every 3 weeks. The
muscle power in her lower limbs recovered substantially
after the second course of chemotherapy, and she
could stand up after the fourth course of chemotherapy.
Delayed surgical excision was planned due to bulky
tumor at difficult sites. However, at the pancytopenic
stage after completion of the fifth course of
chemotherapy, the infant suffered from a neutropenic
fever, which proceeded to septic shock, resulting in
death.
Discussion
PNET within the spinal column may be of the
central or peripheral type in intramedullary, intradural-
extramedullary, or epidural presentation. Deme et al5
reviewed 13 cases of intramedullary or intradural
PNET, and concluded that these neoplasms frequently
disseminate via the cerebrospinal fluid, rarely
metastasize outside the central nervous system, and
appear more commonly in adults than in children. On
the other hand, pPNET located within the epidural
space, as in our case, is very rare and was first reported
by Angervall and Enzinger in 1975.6 Up to the present,
only 3 cases of pPNET within the spinal epidural space
have been reported.
pPNET has the clinical features of aggressive growth
and rapid progression with distant metastasis to bone,
liver and lung, which differs from the central type.
Furthermore, it can be distinguished from the central
type of PNET and other small blue-cell tumors by the
characteristic translocation t(11;22)(q24;q12).7,8 In
our patient, chromosome analysis of the tumor was
not performed because she died before debulking
surgery, and the surgeon was not able to send a
specimen for further cytogenetic study at the initial
biopsy. We could only make the diagnosis of pPNET
according to the location of the tumor (epidural) and
the pathologic report.
In the English literature, the most common
symptoms in patients with pPNET in the spinal column
include back and/or radicular pain and leg paresis
(91.3% of cases), and bladder and bowel dysfunction,
suggesting that the signs and symptoms resulted from
compression of the spinal cord, cauda equine, and
nerve root. As our patient could not express her feeling
of pain, the sign of spinal compression was not detected
until leg paresis appeared. In this situation, consultation
with a pediatric neurologist, neurosurgeon and
oncologist is critical for determining the best course of
emergency management. If lymphoma is highly
suspected, steroids should be administered instead of
surgical decompression. Contrast-enhanced spinal
MRI to examine the extent of involvement should
be arranged immediately, and histopathologic
examinations, together with cytogenetic analysis, are
necessary at tumor biopsy to delineate the tumor and
confirm the diagnosis.
Frequently, laminectomy with tumor resection is
indicated for the relief of neurologic symptoms. In the
literature,9 72.7% of tumors were only partially resected
and resulted from infiltration of surrounding tissues,
as in our patient, and they seemed to have a high
incidence of local recurrence and high mortality.10
Figure 3. Photomicrography (A, = 100; B, = 400) shows small
cells with mild nuclear pleomorphism, scant eosinophilic
cytoplasm, and a fibrillary stroma (hematoxylin & eosin, = 100
and = 400, respectively). These cells are weakly reactive for
epithelial membrane antigen, but nonreactive for glial fibrillary
acidic protein. MIB-1 (a monoclonal antibody that detects
cell-cycle-associated Ki-67 antigen) labeling index is 30%.
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Besides surgical resection, radiotherapy and
chemotherapy form an important adjuvant therapy for
PNET.11,12 The reported doses of radiotherapy
suggested for patients with PNET in the spinal canal
varied between 30.6 and 56 Gy,10 and it is especially
essential in patients with incomplete resection of the
primary tumor. Since our patient was young and
responded well to chemotherapy, radiotherapy was
only considered as adjuvant therapy for local control.
For patients with pPNET, the most common
chemotherapeutic agents used are vincristine,
adriamycin, cyclophosphamide, ifosfamide and
actimomycin-D. Some investigators have reported the
positive impact of high-dose chemotherapy followed
by peripheral blood stem cell transplantation on clinical
outcome,13–15 but others have reported failure in
improving overall survival rates and the increasing
incidence of secondary malignancy. Even with
radiotherapy plus chemotherapy, spinal PNET is
reported to have a poor prognosis, with the 5-year
survival rate ranging from 0% to 37.5%.9
In recent cytogenetic studies, the chromosomal
translocation of t(11;22)(q24;q12) was found to be
highly specific to pPNET, and may result in the
formation of a chimeric gene, EWS/Fli-1.16 It was
reported to act as an alternative transcription factor to
promote the oncogenesis of PNET. Serial reports
showed that the abnormal chromosome 22 may play
an important role in the development of neoplasms,
including epithelioid sarcoma, insulinoma, malignant
meningiomas, follicular thyroid carcinoma, and
malignant rhabdoid tumor. Chromosome 22q11
microdeletion (del 22q11) is implicated in a number of
constructional heart defects, especially in TOF. Recently,
it has also been reported to be associated with the
diverse abnormalities classified under the acronym
CATCH 22. Therefore, abnormalities of chromosome
22 seem to play a role in the development of congenital
heart defects and the oncogenesis of neoplasm. This
11-month-old girl not only suffered from TOF but
also pPNET around the spinal column. We tried to
find out the cytogenetic features of TOF and pPNET
in this patient, but no chromosome abnormality was
found from her peripheral blood specimen.
In conclusion, pPNET rarely originates from the
spinal column, and the prognosis is poor. The initial
presentation in infancy might be leg weakness that can
be easily neglected by parents. Tumor size, extent of
disease, and complete surgical resection may influence
the overall survival rate and incidence of local recurrence.
Surgical resection combined with multiagent
chemotherapy or radiotherapy is recommended.
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